[The oral application of berotec in the therapy of obstructive airway diseases].
The intensity and duration of action of Berotec (fenoterol) syrup in doses of 2.5 mg and 5.0 mg were investigated in an acute cross-over study in comparison with placebo, using the double blind technique. By measurement of the forced expiratory volume (FEV1) and the forced expiratory flow rate (FEF200-1200) significant improvement in pulmonary function could be detected from 1 to 4 hours after administration of 2.5 mg and from 1 to 8 hours after administration fo 5.0 mg Berotec syrup. The intensity of action exhibited a statistically significant dose dependence and was greater after the 5.0 mg dose (p=0.05) than after 2 puffs from Berotec metered aerosol taken by the patients in a pre-test. Minor side effects were observed in 2 cases: in one patient on the 5.0 mg dose they were clearly sympathomimetic and accompanied by a stronger bronchodilating effect.
D000328:Adult; D000336:Aerosols; D000402:Airway Obstruction / Q000188:drug therapy*; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D004341:Drug Evaluation; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000627:therapeutic use*; D005540:Forced Expiratory Flow Rates; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged
D000336:Aerosols; D004983:Ethanolamines; D005280:Fenoterol
Zur oralen Anwendung von Berotec in der Therapie obstruktiver Erkrankungen der Atemwege.